Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Medical Oncology-Lewisburg — Lewisburg, Pennsylvania
- Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Pennsylvania: - Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Pennsylvania: - Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Pennsylvania: - Jefferson Health Honickman Center — Philadelphia, Pennsylvania
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS — Pittsburgh, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Pennsylvania: - Rittenhouse Hematology Oncology — Philadelphia, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- AHN West Penn Hospital — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Pennsylvania: - University of Pittsburgh Medical Center, Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unr…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT05168163
Sites in Pennsylvania: - Allegheny General Hospital — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced un…
Sponsor: Replimune, Inc.
NCT ID: NCT05733598
Sites in Pennsylvania: - University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other p…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06811116
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HC…
Sponsor: Anwaar Saeed
NCT ID: NCT06698250
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric canc…
Sponsor: Anwaar Saeed
NCT ID: NCT03539822
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for emboliz…
Sponsor: Teclison Ltd.
NCT ID: NCT02174549
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of…
Sponsor: Thomas Jefferson University
NCT ID: NCT07145801
Sites in Pennsylvania: - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Sponsor: Diwakar Davar
NCT ID: NCT07223424
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current…
Sponsor: Dan Zandberg
NCT ID: NCT04114136
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Federal
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver t…
Sponsor: VA Office of Research and Development
NCT ID: NCT05842174
Sites in Pennsylvania: - Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embol…
Sponsor: john eisenbrey
NCT ID: NCT06261814
Sites in Pennsylvania: - Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Pennsylvania: - Exelixis Clinical Site #104 — Hershey, Pennsylvania
- Exelixis Clinical Site #98 — Philadelphia, Pennsylvania
- Exelixis Clinical Site #32 — Pittsburgh, Pennsylvania
- Exelixis Clinical Site #24 — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT…
Sponsor: Alnylam Pharmaceuticals
NCT ID: NCT06600321
Sites in Pennsylvania: - Clinical Trial Site — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events a…
Sponsor: AbbVie
NCT ID: NCT06858813
Sites in Pennsylvania: - Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269 — Philadelphia, Pennsylvania
Phase 1 Recruiting Industry
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizuma…
Sponsor: BeOne Medicines
NCT ID: NCT06427941
Sites in Pennsylvania: - Upmc Hillman Cancer Center(Univ of Pittsburgh) — Pittsburgh, Pennsylvania
Phase 1 Recruiting Academic/Other
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve th…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT ID: NCT07001592
Sites in Pennsylvania: - AHN West Penn Hospital — Pittsburgh, Pennsylvania